| Basics |
Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
|
| IPO Date: |
May 23, 1996 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$14.15B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.85 | 1.96%
|
| Avg Daily Range (30 D): |
$1.32 | 0.93%
|
| Avg Daily Range (90 D): |
$1.51 | 1.12%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.69M |
| Avg Daily Volume (30 D): |
.62M |
| Avg Daily Volume (90 D): |
.68M |
| Trade Size |
| Avg Trade Size (Sh.): |
93 |
| Avg Trade Size (Sh.) (30 D): |
40 |
| Avg Trade Size (Sh.) (90 D): |
42 |
| Institutional Trades |
| Total Inst.Trades: |
11,888 |
| Avg Inst. Trade: |
$3.82M |
| Avg Inst. Trade (30 D): |
$14.23M |
| Avg Inst. Trade (90 D): |
$10.47M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$8.88M |
| Avg Closing Trade (30 D): |
$21.42M |
| Avg Closing Trade (90 D): |
$19.85M |
| Avg Closing Volume: |
97.11K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$1.09
|
$.08
|
|
Diluted EPS
|
|
$1.06
|
$.08
|
|
Revenue
|
$
|
$ 687.5M
|
$ 572.6M
|
|
Gross Profit
|
$
|
$ 676.2M
|
$ 563.4M
|
|
Net Income / Loss
|
$
|
$ 107.5M
|
$ 7.9M
|
|
Operating Income / Loss
|
$
|
$ 145.6M
|
$ 23.6M
|
|
Cost of Revenue
|
$
|
$ 11.3M
|
$ 9.2M
|
|
Net Cash Flow
|
$
|
$ 69.9M
|
$ -38.9M
|
|
PE Ratio
|
|
|
|
|
|
|
